nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2006 | Editorial

Which radionuclides will nuclear oncology need tomorrow?

verfasst von: Jacques Barbet, Jean-François Chatal, François Gauché, Jacques Martino

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Excerpt

The role of nuclear medicine in oncology has changed dramatically in recent years owing to outstanding technical advances in imaging and therapy. This progress is opening up new, exciting perspectives which should ensure that nuclear medicine techniques will become standard diagnostic and therapeutic modalities, complementing conventional modalities. Positron emission tomography/computed tomography (PET/CT) technology with ¹⁸F-fluorodeoxyglucose (FDG), which has been developed clinically in less than 10 years, is now accepted as the gold standard in oncological imaging [1]. Moreover, a number of other fluorinated radiopharmaceuticals are being evaluated for their ability to complement FDG [2], and some could be approved for routine clinical use in the future. …

The name ARRONAX also refers to Professor Aronnax, a character in the novel Twenty Thousand Leagues Under the Sea by the famous French writer Jules Verne, who was born in Nantes in 1828.

Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238:405–22CrossRef

Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1182–206PubMedCrossRef

Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin’s lymphoma: the European perspective. Cancer Biother Radiopharm 2006;21:1–4PubMedCrossRef

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696–704PubMedCrossRef

Radford JA, Ketterer N, Sebban C. Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of multicenter, phase III clinical trial. Blood 2003;102:408aCrossRef

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–62PubMedCrossRef

Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189–94PubMedCrossRef

Moertel CM, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–23PubMedCrossRef

Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 1994;73:1505–8PubMedCrossRef

10.

Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with ¹³¹I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763–70PubMedCrossRef

11.

Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705–1711

12.

Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006;24:115–22PubMedCrossRef

13.

Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003;44:1282–83PubMed

14.

Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46(Suppl 1):164s–71sPubMed

15.

DeNardo GL, DeNardo SJ, O’Donnell RT, Kroger LA, Kukis DL, Meares CF, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma. Clin Lymphoma 2000;1:118–26PubMedCrossRef

16.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using ¹⁷⁷Lu- and ⁹⁰Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13s–7sPubMed

17.

Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601–14PubMedCrossRef

18.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233–9PubMed

19.

Sharkey RM, Cardillo TM, Rossi EA, Chang C-H, Karacay H, McBride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nature Med 2005;11:1250–5PubMedCrossRef

Titel: Which radionuclides will nuclear oncology need tomorrow?
verfasst von: Jacques Barbet
Jean-François Chatal
François Gauché
Jacques Martino
Publikationsdatum: 01.06.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0116-4

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: detection by 18F-FDG PET

Myocardial glucose utilisation in type II diabetes mellitus patients treated with sulphonylurea drugs

Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L-tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat

Robustness of estimation of differential renal function in infants and children with unilateral prenatal diagnosis of a hydronephrotic kidney on dynamic renography: How real is the supranormal kidney?

Synthesis and evaluation of radioiodinated (S,S)-2-(α-(2-iodophenoxy)benzyl)morpholine for imaging brain norepinephrine transporter

Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′